PI3K and P110delta Hyperactivation Syndrome

Clinical trial pipeline · Data from ClinicalTrials.gov

See which PI3K and P110delta Hyperactivation Syndrome trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (1 shown)

UnknownPhase 2/3

NCT06293716

CVL237 Tablets for APDS/PASLI

This study was designed to evaluate the efficacy and safety of CVL237 tablets in patients with APDS/PASLI (activated phosphoinositol 3-kinase δ syndrome /p110 d…

China35 participantsStarted 2024-03-30

Treatment: CVL237 tablets, CVL237 placebo tablets